Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(8):718-721; doi:10.1093/jnci/91.8.718
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Uzzo, R. G.
Right arrow Articles by Finke, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uzzo, R. G.
Right arrow Articles by Finke, J. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 8, 718-721, April 21, 1999
© 1999 Oxford University Press

BRIEF COMMUNICATIONS

Alterations in NF{kappa}B Activation in T Lymphocytes of Patients With Renal Cell Carcinoma

Robert G. Uzzo, Peter E. Clark, Patricia Rayman, Tracy Bloom, Lisa Rybicki, Andrew C. Novick, Ronald M. Bukowski, James H. Finke

Affiliations of authors: R. G. Uzzo, P. E. Clark (Departments of Immunology, Lerner Research Institute, and Urology), P. Rayman, T. Bloom (Department of Immunology, Lerner Research Institute), L. Rybicki (Department of Biostastics), A. C. Novick (Department of Urology), R. M. Bukowski (Departments of Immunology, Lerner Research Institute, and Urology, and Experimental Therapeutics Program), J. H. Finke (Departments of Immunology, Lerner Research Institute, and Urology, and Experimental Therapeutics Program), The Cleveland Clinic Foundation, OH.

Correspondence to: Robert G. Uzzo, M.D., Department of Immunology, NB3-29, The Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195.

T cells represent an important component in the development of an effective antitumor immune response. Although most solid tumors are infiltrated with T lymphocytes, including some clones capable of preferentially recognizing malignant cells, T-cell immunity fails to develop adequately in patients with tumors (1-4). Defects in proliferation and effector functions have been noted in peripheral blood T cells, while more pronounced alterations have been reported for T cells infiltrating the tumor (5,6). Moreover, cytokine gene expression normally associated with the development of an effective antitumor immune response is absent in the tumor (7).

Alterations in expression and activity of intracellular signaling elements have been reported in T cells from patients with tumors (8). These include defective activation of the transcription factor NF{kappa}B in both tumor-bearing mice and patients with renal cell carcinoma (RCC) (9,10. . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
T. Ando, K. Mimura, C. C. Johansson, M. G. Hanson, D. Mougiakakos, C. Larsson, T. Martins da Palma, D. Sakurai, H. Norell, M. Li, et al.
Transduction with the Antioxidant Enzyme Catalase Protects Human T Cells against Oxidative Stress
J. Immunol., December 15, 2008; 181(12): 8382 - 8390.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. Kim, E. Wieckowski, D. D. Taylor, T. E. Reichert, S. Watkins, and T. L. Whiteside
Fas Ligand-Positive Membranous Vesicles Isolated from Sera of Patients with Oral Cancer Induce Apoptosis of Activated T Lymphocytes
Clin. Cancer Res., February 1, 2005; 11(3): 1010 - 1020.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Gati, N. Guerra, C. Gaudin, S. Da Rocha, B. Escudier, Y. Lecluse, A. Bettaieb, S. Chouaib, and A. Caignard
CD158 Receptor Controls Cytotoxic T-Lymphocyte Susceptibility to Tumor-Mediated Activation-Induced Cell Death by Interfering with Fas Signaling
Cancer Res., November 1, 2003; 63(21): 7475 - 7482.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. K. Batra, Y. Lin, S. Sharma, M. Dohadwala, J. Luo, M. Pold, and S. M. Dubinett
Non-Small Cell Lung Cancer-derived Soluble Mediators Enhance Apoptosis in Activated T Lymphocytes through an I{kappa}B Kinase-dependent Mechanism
Cancer Res., February 1, 2003; 63(3): 642 - 646.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K.-J. Malmberg, R. Lenkei, M. Petersson, T. Ohlum, F. Ichihara, B. Glimelius, J.-E. Frodin, G. Masucci, and R. Kiessling
A Short-Term Dietary Supplementation of High Doses of Vitamin E Increases T Helper 1 Cytokine Production in Patients with Advanced Colorectal Cancer
Clin. Cancer Res., June 1, 2002; 8(6): 1772 - 1778.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. G. S. Buggins, D. Milojkovic, M. J. Arno, N. C. Lea, G. J. Mufti, N. S. B. Thomas, and W. J. R. Hirst
Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-{kappa}B, c-Myc, and pRb Pathways
J. Immunol., November 15, 2001; 167(10): 6021 - 6030.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K.-J. Malmberg, V. Arulampalam, F. Ichihara, M. Petersson, K. Seki, T. Andersson, R. Lenkei, G. Masucci, S. Pettersson, and R. Kiessling
Inhibition of Activated/Memory (CD45RO+) T Cells by Oxidative Stress Associated with Block of NF-{kappa}B Activation
J. Immunol., September 1, 2001; 167(5): 2595 - 2601.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Gati, N. Guerra, J. Giron-Michel, B. Azzarone, E. Angevin, A. Moretta, S. Chouaib, and A. Caignard
Tumor Cells Regulate the Lytic Activity of Tumor-specific Cytotoxic T Lymphocytes by Modulating the Inhibitory Natural Killer Receptor Function
Cancer Res., April 1, 2001; 61(8): 3240 - 3244.
[Abstract] [Full Text]